S6K1- amplificated tumours treated with palbociclib did not regress (P = 0.721, Fig. 6G), thus confirming the ability of S6K1 amplification to confer resistance to palbociclib in vivo. This evidence concerns the gene RPS6KB1 and neoplasm.